| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9fbdda83334a24a3ab509ecbda30139c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f2cf8d712970ee1ea1bd660ceb8b5055 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55511 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H5-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
2007-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ba624c3d7557ac0226bc681b3a37d29
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb4cc38efeef0ee41633a01fc3613e34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c391000ba4f42be7b70a41c483ea2500
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9800a958f77b61622e4d5895edc072c7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b52f391f23728234e6fb7e8cc5ca765
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6fb2638257804edf98ee18b5c9dbcf8 |
| publicationDate |
2009-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2089051-A2 |
| titleOfInvention |
Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes |
| abstract |
The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epitopes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal. |
| priorityDate |
2006-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |